Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

HUTCHMED's Orpathys-Tagrisso Combination Cuts Death Risk 32% in Phase III Lung Cancer Trial

By Public Technologies
  • HUTCHMED announced European and Japanese regulatory acceptance for review of Orpathys combined with Tagrisso for MET-driven, EGFR-mutated lung cancer.
  • Applications target advanced non-small cell lung cancer with MET overexpression or amplification following progression on EGFR-targeted therapy.
  • The filings follow a US Food and Drug Administration application submitted in September 2026.
  • The Phase III SAFFRON trial showed improved survival and delayed disease progression versus platinum-based chemotherapy, with no new safety concerns.
  • Results were already presented at the ESMO 2026 Presidential Symposium and simultaneously published in The New England Journal of Medicine.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HUTCHMED (China) Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611011900PRIMZONEFULLFEED9857409) on November 02, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.